ストックスクリーナーアプリを入手
8.16
0.00%
0.00
アフターアワーズ：
7.83
-0.33
-4.04%
前日終値:
$8.16
開ける：
$8.4999
24時間の取引高:
1,810
Relative Volume:
0.21
時価総額：
$39.49M
収益：
$2.61M
当期純損益:
$1.69M
株価収益率:
27.17
EPS:
0.3003
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+5.02%
1か月 パフォーマンス:
+14.44%
6か月 パフォーマンス:
-9.70%
1年 パフォーマンス:
-4.00%
1日の値動き範囲:
$7.7901
$8.4999
1週間の範囲:
$7.55
$8.4999
52週間の値動き範囲:
$6.55
$10.00
Daxor Corporation Stock (DXR) Company Profile
名前
Daxor Corporation
セクター
電話
212-330-8500
住所
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
DXR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
8.16 | 39.49M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
476.78 | 170.05B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
222.79 | 63.97B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
86.81 | 42.94B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
219.72 | 32.28B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
34.55 | 17.64B | 17.28B | 108.00M | 391.00M | 0.20 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-05-16 | 開始されました | Ascendiant Capital Markets | Buy |
Daxor Corporation (DXR) 最新ニュース
Daxor Corporation (NASDAQ:DXR) Q4 2024 Earnings Call Transcript - MSN
Daxor Corporation Reports Strong 2024 Financial Growth - TipRanks
Daxor CFO Michel Robert J purchases $8,000 in company stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases $25,804 in company stock - Investing.com
Daxor CFO Michel Robert J purchases $8,000 in company stock - Investing.com
Daxor Corporation Reports Robust Growth in Earnings Call - TipRanks
Earnings call transcript: Daxor Q4 2024 sees 116.5% revenue growth - Investing.com India
Earnings call transcript: Daxor Q4 2024 sees 116.5% revenue growth By Investing.com - Investing.com UK
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - GlobeNewswire
Daxor Corporation Reports Increase in NAV to $7.25 Per - GlobeNewswire
How Daxor Achieved Triple-Digit Revenue Growth: 60% Kit Sales Spike and DoD Contract Success - StockTitan
Daxor Corporation to Host Investor Conference Call to - GlobeNewswire
When Will Daxor Share Its 2024 Results? Key Date for Blood Volume Tech Investors - StockTitan
(DXR) Investment Report - Stock Traders Daily
Daxor Corporation CEO And President Michael Feldschuh Provides Corporate Update In Letter To Shareholders - Marketscreener.com
How Daxor Achieved 116% Revenue Growth and Cash-Flow Break-Even: CEO Reveals Strategy - StockTitan
Daxor reports significant growth and strategic advances - Investing.com
Daxor reports significant growth and strategic advances By Investing.com - Investing.com South Africa
Daxor Corporation Reports Significant Growth and Strategic Developments in Blood Volume Measurement Technology - Nasdaq
How Daxor Doubled Revenue and Reached Cash-Flow Break-Even: CEO's Strategic Vision Revealed - StockTitan
How Daxor's 116.5% Revenue Explosion Could Transform Its Medical Diagnostics Business - StockTitan
Daxor Expands Blood Volume Analysis Services At Major Midwest Healthcare Center - Marketscreener.com
Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center - The Manila Times
How Daxor's No-Capital-Cost Diagnostic Service Is Quietly Expanding Across Major Healthcare Systems - StockTitan
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals - GlobeNewswire
Can Daxor's Hospital Expansion Strategy Transform Critical Care Outcomes? - StockTitan
Head to Head Comparison: Daxor (NASDAQ:DXR) versus iRhythm Technologies (NASDAQ:IRTC) - Defense World
Long Term Trading Analysis for (DXR) - Stock Traders Daily
Daxor Corporation Announces New Data on Blood Volume - GlobeNewswire
Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025 - The Manila Times
Duke and Yale Studies Validate Daxor's Blood Volume Analysis Superior Accuracy | DXR Stock News - StockTitan
Daxor to Exhibit at World's Largest Critical Care Conference - GlobeNewswire
Revolutionary ICU Blood Analysis Slashes Death Rates: Daxor's Game-Changing Data Revealed - StockTitan
DXRDaxor Corporation Latest Stock News & Market Updates - StockTitan
Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure - GlobeNewswire
Hidden Heart Failure Risk Affects Millions: Daxor's Revolutionary Blood Test Unlocks Life-Saving Treatment Path - StockTitan
Daxor Corporation Announces Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care - Marketscreener.com
Daxor Hikeson Blood Study - Baystreet.ca
New Multicenter Study Highlights Utility of Daxor’s Blood Volume Analysis in Heart Failure Care - GlobeNewswire
Major Clinical Study: Revolutionary Heart Failure Diagnostic Achieves Near-Perfect Accuracy - StockTitan
Daxor stock hits 52-week low at $6.83 amid market challenges - MSN
(DXR) Investment Analysis and Advice - Stock Traders Daily
Where are the Opportunities in (DXR) - Stock Traders Daily
Reviewing Becton, Dickinson and Company (NYSE:BDX) and Daxor (NASDAQ:DXR) - Defense World
(DXR) Technical Pivots with Risk Controls - Stock Traders Daily
Head to Head Contrast: Daxor (NASDAQ:DXR) versus Titan Medical (NASDAQ:TMDIF) - Defense World
Daxor Corporation (DXR) 財務データ
収益
当期純利益
現金流量
EPS
2.47%
0.19%
大文字化:
|
ボリューム (24 時間):